Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Belantamab mafodotin (Synonyms: GSK2857916, GSK 2857916, Belantamab mafodotin-blm)

Catalog No. T77903 Copy Product Info
🥰Excellent
Belantamab mafodotin (GSK2857916) is an antibody-drug conjugate targeting B-cell maturation antigen (BCMA) that enhances immune cell infiltration and activation within tumors and delays tumor growth. It is used in studies of multiple myeloma.

Belantamab mafodotin

Copy Product Info
🥰Excellent
Catalog No. T77903
Synonyms GSK2857916, GSK 2857916, Belantamab mafodotin-blm

Belantamab mafodotin (GSK2857916) is an antibody-drug conjugate targeting B-cell maturation antigen (BCMA) that enhances immune cell infiltration and activation within tumors and delays tumor growth. It is used in studies of multiple myeloma.

Belantamab mafodotin
Cas No. 2050232-20-5
TargetMol | Customer service
Customer service consultation
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$297In StockIn Stock
5 mg$778-In Stock
10 mg$1,230-In Stock
25 mg$1,830-In Stock
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.14% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information

Product Introduction

Bioactivity
Description
Belantamab mafodotin (GSK2857916) is an antibody-drug conjugate targeting B-cell maturation antigen (BCMA) that enhances immune cell infiltration and activation within tumors and delays tumor growth. It is used in studies of multiple myeloma.
Targets&IC50
BCMA (human):1 nM (Kd)
In vitro
Belantamab mafodotin is an immune conjugate (ADC) that targets B cell maturation antigens.
The Kd value of Belantamab mafodotin binding human BCMA protein was 1 nM.
Belantamab mafodotin induces G2/M phase arrest in multiple myeloma cells in a dose - and time-dependent manner. [1]
In vivo
Belantamab mafodotin significantly improved survival in mice with OPM2 tumors. [1]
SynonymsGSK2857916, GSK 2857916, Belantamab mafodotin-blm
Reactivity
Human
Verified Activity
Immobilized Human BCMA Protein (ECD, His) at 2 μg/mL can bind Belantamab mafodotin. The EC50 is 0.02634 μg/mL
verifiedActivity
Application
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
MMAF
Antigen Details
Gene ID
Uniprot ID
TargetTNFRSF17/BCMA/CD269
Chemical Properties
Molecular Weight146.06 kDa
Cas No.2050232-20-5
Antibody Information
IsotypeIgG1 kappa-McMMAF
Recommended Isotype Control
Storage & Solubility Information
StorageShipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Keywords

Related Tags: buy Belantamab mafodotin | purchase Belantamab mafodotin | Belantamab mafodotin cost | order Belantamab mafodotin | Belantamab mafodotin in vivo | Belantamab mafodotin in vitro | Belantamab mafodotin molecular weight